Brand and Other Names:Mycobutin
- Classes: Antitubercular Agents
Dosing & Uses
Dosage Forms & Strengths
Indicated for prefention of disseminated Mycobacterium avium complex (MAC) disease in paitents with advanced HIV infection
300 mg PO qDay
Patients with N/V diathesis: 150 mg PO BID with food
Active TB (off-label)
5 mg/kg PO qD or 2-3x/week + other antitubercular agents, no more than 300 mg/dose
MAC Treatment (Orphan)
Treatment of disseminated Mycobacterium avium complex disease
Orphan indication sponsor
- Pfizer, Inc; 235 East 42nd Street; New York, NY 10017
Crohn Disease (Orphan)
Combination of clarithromycin, rifabutin, and clofazimine for treatment of pediatric Crohn disease
Orphan indication sponsor
- RedHill Biopharma Ltd; 42 Givati St; Israel
CrCl<30mL/min dose should be reduced by 50%
Other Indications & Uses
Off-label: resistant H. pylori (300 mg/d + amoxicillin 1000 mg BID + pantoprazole 40 mg BID x10 d); Treatment of active TB (concomitant with other anti-TB agents)
Dosage Forms & Strengths
Mycobacterium Avium Complex (MAC)
Treatment: 5-10 mg/kg PO qD ; no more than 300 mg/d
Prophylaxis: 1st episode in HIV/recurrence: 5 mg/kg PO qD; no more than 300 mg/d
Active TB with HIV (Off-label)
10-20 mg/kg PO qD OR 2x/week + other antitubercular agents; no more than 300 mg/dose
Serious - Use Alternative
Significant - Monitor Closely
Discoloration of urine (30%)
Incr AST/ALT (7-9%)
Abdominal pain (4%)
Blood and lymphatic system disorders: Agranulocytosis, lymphopenia, granulocytopenia, white blood cell ccount decreased, neutrophil count ddecreased), platelet count decreased
Immune system disorders: Hypersensitivity, bronchospasm
Gastrointestinal disorders: Clostridium difficile colitis/ Clostridium difficile associated diarrhea
Pyrexia, rash and other hypersensitivity reactions such as eosinophilia, bronchospasm and shock might occur, as has been seen with other antibacterials; a limited number of skin discoloration have been reported
Hypersensitivity to rifamycins
Concomitant live bacterial vaccines
Monitor hematologic status
Eye pain, redness, loss of vision may indicate inflammatory ocular condition
Joint stiffness, swelling, tenderness or paresthesia may indicate arthralgias or myositis
May have brown-orange color of urine, feces, saliva, sputum, perspiration, tears, & skin
Pregnancy & Lactation
Pregnancy Category: B
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Absorption: readily, 53%
Distribution: body tissues including the lungs, liver, spleen, eyes, & kidneys
Vd: 9.32 L/kg
Protein Bound: 85%
Bioavailability: absolute: HIV: 20%
Half-Life, Elim45 hr (range: 16-69 hr)
Peak Plasma Time: 2-4 hr
Metabolism: hepatic CYP3A4 to active and inactive metabolites
Urine: 10% as unchanged drug, 53% as metabolites
Feces: 10% as unchanged drug, 30% as metabolites
Mechanism of Action
Inhibits DNA-dependent RNA polymerase
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs